{"id":2162,"date":"2026-06-08T09:35:00","date_gmt":"2026-06-08T09:35:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/06\/08\/three-types-of-progressive-disability\/"},"modified":"2026-06-08T09:35:00","modified_gmt":"2026-06-08T09:35:00","slug":"three-types-of-progressive-disability","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/06\/08\/three-types-of-progressive-disability\/","title":{"rendered":"Three types of Progressive Disability"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2026%2F06%2Fthree-types-of-progressive-disability%2F&amp;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p class=\"wp-block-paragraph\">The CONSONANCE trial was a trial of ocrelizumab<\/p>\n<p class=\"wp-block-paragraph\">De Meo E, Jolly AE, Ganzetti M, Prados Carrasco F, Kanber B, Stutters J, McManus D, Kazlauskaite A, Craveiro L, Eshaghi A, Cole J, Chard D, Barkhof F. Disability profiles in progressive multiple sclerosis reflect pathology distribution, independent of clinical phenotype. Brain Commun. 2026 May 2;8(3):fcag162. doi: 10.1093\/braincomms\/fcag162.<\/p>\n<p class=\"wp-block-paragraph\">Multiple sclerosis (MS) is a clinically heterogeneous disease affecting both neurological and cognitive functions. In this study, <strong>we defined clinical profiles based on combined cognitive and motor assessments in progressive MS patients<\/strong>, examined their overlap with classical progressive phenotypes and linked each profile to MRI measures of network disconnection and grey matter atrophy. We analyzed baseline data from 580 participants [277 primary progressive (PP)MS, 303 secondary progressive (SP)MS] in the phase 3b CONSONANCE (<a href=\"http:\/\/clinicaltrials.gov\/show\/NCT03523858\">NCT03523858<\/a>) study. Clinical assessments included Expanded Disability Status Scale, 9-Hole Peg Test (Hand function), timed 25-Foot Walk Test (walking test), Symbol Digit Modalities Test (cognitive test) and Brief Visuospatial Memory Test Revised (co-ordination and memory test)&#8230;.. Latent profile analysis (LPA) identified disability profiles from clinical data&#8230;. Based on prevailing clinical manifestation, LPA delineated three profiles: <strong>motor disability<\/strong> (<em>n<\/em>\u00a0= 138, 23.8%), <strong>cognitive disability<\/strong> (<em>n<\/em>\u00a0= 181, 31.2%) and <strong>global (Both motor and cognitive) disability<\/strong> (<em>n<\/em>\u00a0= 261, 45.0%). Profile prevalence did not differ by <em>clinical progressive subtype<\/em>&#8230;..<em>were associated with MRI changes<\/em>. <strong>Our findings reveal that progressive MS encompasses at least three clinically and biologically distinct subtypes transcending the traditional PPMS\/SPMS divide.<\/strong> The cognitive disability profile is driven by focal network disconnection and targeted grey matter loss in critical cognitive hubs, whereas the global disability profile reflects widespread grey matter atrophy across motor and associative regions. Identifying these profiles could be useful in clinical trials by matching outcome measures to underlying patterns of pathology and their clinical manifestations.<\/p>\n<p class=\"wp-block-paragraph\">COI: None<\/p>\n<p class=\"wp-block-paragraph\">Disclaimer. I removed many of the technical elements<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2026\/06\/three-types-of-progressive-disability\/?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=three-types-of-progressive-disability\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet The CONSONANCE trial was a trial of ocrelizumab De Meo E, Jolly AE, Ganzetti M, Prados Carrasco F, Kanber B, Stutters J, McManus D, Kazlauskaite A, Craveiro L, Eshaghi A, Cole J, Chard D, Barkhof F. Disability profiles in progressive multiple sclerosis reflect pathology&hellip;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-2162","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=2162"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2162\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=2162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=2162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=2162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}